Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.20.

A number of equities analysts have recently weighed in on RXRX shares. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Accel Wealth Management bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $310,000. Avanza Fonder AB purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $580,000. Institute for Wealth Management LLC. bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $3,928,000. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $23,429,000. Finally, Invesco Ltd. boosted its stake in Recursion Pharmaceuticals by 54.6% during the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company's stock valued at $1,207,000 after buying an additional 63,068 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $5.70 on Monday. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -3.73 and a beta of 1.00. The company's fifty day moving average price is $5.82 and its two-hundred day moving average price is $6.75. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. During the same period in the prior year, the firm earned ($0.42) earnings per share. Recursion Pharmaceuticals's revenue was down 57.8% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.